Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

NCT07388563 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07388563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07388563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Recruiting
Start date
March 26, 2026
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult t-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, lymphoma, t cell, peripheral, monomorphic epitheliotropic intestinal t-cell lymphoma, t-cell lymphoma